PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

NCT03809988

Last updated date
Study Location
CHD Vendee
La Roche-sur-Yon, , 85925, France
Contact
+34 687 246 755

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+34 687 246 755

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer, Advanced Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Female patients over 18 years of age.

2. Pre-menopausal women provided they are being treated with a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/Follicle-stimulating hormone (FSH) must be confirmed analytically) prior to study entry or post- menopausal women as defined by any of the following criteria:

1. Age ≥60 years;

2. Age <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH level within the laboratory's reference range for postmenopausal females;

3. Documented bilateral oophorectomy.

3. Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 1.

4. Life expectancy greater or equal to 12 weeks.

5. Histologically proven diagnosed of ABC not amenable to curative treatment.

6. Documented recurrent ER-positive and/or progesterone receptor (PgR)-positive (with ≥1% positive stained cells (according to NCCN National Comprehensive Cancer Network and ASCO American Society of Clinical Oncology guidelines) and HER2-negative (0-1+ by immunohistochemistry (IHC) or 2+ and negative by in situ hybridization (ISH) test) breast cancer in the advanced setting.

7. Radiological or clinical evidence of disease progression on first- line combination of palbociclib plus endocrine therapy (aromatase inhibitor (AI) or fulvestrant). Patients previously treated with the combination of palbociclib and tamoxifen will be excluded.

8. Patients have achieved clinical benefit criteria to a first-line palbociclib-based endocrine regimen (defined as at least stable disease ≥ 24 weeks or partial or complete response confirmed or unconfirmed).

9. Patients must have been treated with a stable minimum dose of 100 mg palbociclib during the last 2 cycles of the prior palbociclib-based regimen.

10. Last dose of palbociclib administered not later than 8 weeks and not earlier than 7 days from study entry, with the exception of patients relapsing on a palbociclib-based regimen in the adjuvant setting.

11. Patients should not have been treated in the advanced setting with at least one of these endocrine therapy options: either fulvestrant or AI.

12. Patients must have measurable disease or evaluable disease according to RECIST criteria v.1.1. Patients with only bone lesions are eligible.

13. Willingness and ability to provide tumor biopsy (if feasible) both at the time of the inclusion and after disease progression in order to perform exploratory studies. If not feasible, patient eligibility should be evaluated by a Sponsor's qualified designee.

14. Patients agree to collection of blood samples (liquid biopsy) at the time of inclusion, after 2 weeks of treatment, and upon progression or study termination.

15. Adequate organ function: (Hematological, hepatic and renal)

16. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

17. Patients have been informed about the nature of study, and have agreed to participate in the study, and signed the informed consent form prior to participation in any study-related activities.

18. Resolution of all acute toxic effects of prior anti-cancer therapy to grade 1

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. HR or HER2 unknown disease.


2. HER2-positive disease based on local laboratory results (performed by IHC / ISH test).


3. Locally ABC candidate for curative treatment.


4. Formal contraindication to endocrine therapy defined as visceral crisis and rapidly or
symptomatic progressive visceral disease.


5. Prior therapy with any other CDK4/6 inhibitor different from palbociclib.


6. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases,
carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms,
cerebral edema, and/or progressive growth. Patients with a history of CNS metastases
or cord compression are eligible if they have been definitively treated and are
clinically stable off anticonvulsants and steroids for at least 4 weeks before
randomization.


7. Patients are currently receiving food or drugs known to be strong inducers or
inhibitors of CYP3A4.


8. Current or prior malignancy which could affect compliance with the protocol or
interpretation of results. Patients with curatively- treated non-melanoma skin cancer,
non-muscle-invasive bladder cancer, or carcinoma in situ, among others, are generally
eligible.


9. No other systemic therapy for metastatic disease including chemotherapy,
immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine
therapy excluding first-line palbociclib-based regimen.


10. Major surgery (defined as requiring general anesthesia) or significant traumatic
injury within 2 weeks of start of study drug, or patients who have not recovered from
the side effects of any major surgery, or patients who may require major surgery
during the study.


11. Radiotherapy or limited-field palliative radiotherapy within 7 days prior to study
enrolment, or patients who have not recovered from radiotherapy-related toxicities to
baseline or grade ≤ 1 and/or from whom ≥ 25% of the bone marrow has been previously
irradiated.


12. Use of concurrent investigational agents or other concomitant anticancer therapies.


13. Active bleeding diathesis, previous history of bleeding diathesis, or chronic
anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon
as it is used as prophylaxis intention).


14. Serious concomitant systemic disorder (e.g., active infection including HIV, or
cardiac disease) incompatible with the study (at the discretion of investigator).


15. Unable to swallow capsules or tablets.


16. History of malabsorption syndrome or other condition that would interfere with enteral
absorption.


17. Any of the following within 6 months of randomization:


myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of
NCI-CTCAE v.5.0 grade ≥2, coronary/peripheral artery bypass graft, symptomatic
congestive heart failure, cerebrovascular accident including transient ischemic
attack, or symptomatic pulmonary embolism.


18. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade ≥ 2.


19. Known hypersensitivity to palbociclib or any of its excipients.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast Cancer, Advanced Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of BreastPALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
NCT03809988
  1. La Roche-sur-Yon,
  2. Paris,
  3. Paris,
  4. Strasbourg,
  5. Dresden,
  6. Essen,
  7. Essen,
  8. Frankfurt,
  9. Munich,
  10. Münster,
  11. Potsdam,
  12. Trier,
  13. Brescia,
  14. Milano,
  15. Prato,
  16. Roma,
  17. Swansea,
  18. Besançon,
  19. Dijon,
  20. Badalona, Barcelona
  21. Castello, Castelló
  22. A Coruña,
  23. Barcelona,
  24. Barcelona,
  25. Barcelona,
  26. Bilbao,
  27. Cáceres,
  28. Girona,
  29. Lleida,
  30. Madrid,
  31. Madrid,
  32. Madrid,
  33. Málaga,
  34. Palma De Mallorca,
  35. Reus,
  36. Sevilla,
  37. Sevilla,
  38. Valencia,
  39. Valencia,
  40. Valencia,
  41. Valencia,
  42. Vigo,
  43. Zaragoza,
  44. Zaragoza,
  45. Glasgow,
  46. London,
  47. Maidstone,
  48. Truro,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
Official Title  ICMJE International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.
Brief Summary Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)
Detailed Description Pre- and post-menopausal women age ? 18 years with HR-positive and HER2-negative with ABC that had previously received first-line endocrine therapy in combination with palbociclib and had achieved clinical benefit during palbociclib-based treatment. Patients relapsing on a palbociclib-based regimen in the adjuvant setting are also eligible. Patients are not eligible if they are candidates for a local treatment with a curative intention. Evidence of either measurable and biopsiable metastatic disease (as for Response Evaluation Criteria In Solid Tumors (RECIST v.1.1)) or non-measurable disease with bone lesion is required. Pre-menopausal women must be under treatment with luteinizing hormone-releasing hormone (LHRH) analogues.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Randomized 2:1
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Breast Cancer
  • Advanced Breast Cancer
  • Hormone Receptor Positive Tumor
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Intervention  ICMJE
  • Drug: Palbociclib
    Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
    Other Name: IBRANCE
  • Drug: Endocrine therapy
    Endocrine therapy alone (letrozole or fulvestrant)
    Other Names:
    • letrozole
    • fulvestrant
Study Arms  ICMJE
  • Experimental: Interventional Arm (Arm A)
    Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
    Interventions:
    • Drug: Palbociclib
    • Drug: Endocrine therapy
  • Active Comparator: Control Arm (Arm B)
    Patients will receive endocrine therapy (letrozole or fulvestrant).
    Intervention: Drug: Endocrine therapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 16, 2019)
198
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 2023
Estimated Primary Completion Date August 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Female patients over 18 years of age.
  2. Pre-menopausal women provided they are being treated with a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/Follicle-stimulating hormone (FSH) must be confirmed analytically) prior to study entry or post- menopausal women as defined by any of the following criteria:

    1. Age ?60 years;
    2. Age <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH level within the laboratory's reference range for postmenopausal females;
    3. Documented bilateral oophorectomy.
  3. Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 1.
  4. Life expectancy greater or equal to 12 weeks.
  5. Histologically proven diagnosed of ABC not amenable to curative treatment.
  6. Documented recurrent ER-positive and/or progesterone receptor (PgR)-positive (with ?1% positive stained cells (according to NCCN National Comprehensive Cancer Network and ASCO American Society of Clinical Oncology guidelines) and HER2-negative (0-1+ by immunohistochemistry (IHC) or 2+ and negative by in situ hybridization (ISH) test) breast cancer in the advanced setting.
  7. Radiological or clinical evidence of disease progression on first- line combination of palbociclib plus endocrine therapy (aromatase inhibitor (AI) or fulvestrant). Patients previously treated with the combination of palbociclib and tamoxifen will be excluded.
  8. Patients have achieved clinical benefit criteria to a first-line palbociclib-based endocrine regimen (defined as at least stable disease ? 24 weeks or partial or complete response confirmed or unconfirmed).
  9. Patients must have been treated with a stable minimum dose of 100 mg palbociclib during the last 2 cycles of the prior palbociclib-based regimen.
  10. Last dose of palbociclib administered not later than 8 weeks and not earlier than 7 days from study entry, with the exception of patients relapsing on a palbociclib-based regimen in the adjuvant setting.
  11. Patients should not have been treated in the advanced setting with at least one of these endocrine therapy options: either fulvestrant or AI.
  12. Patients must have measurable disease or evaluable disease according to RECIST criteria v.1.1. Patients with only bone lesions are eligible.
  13. Willingness and ability to provide tumor biopsy (if feasible) both at the time of the inclusion and after disease progression in order to perform exploratory studies. If not feasible, patient eligibility should be evaluated by a Sponsor's qualified designee.
  14. Patients agree to collection of blood samples (liquid biopsy) at the time of inclusion, after 2 weeks of treatment, and upon progression or study termination.
  15. Adequate organ function: (Hematological, hepatic and renal)
  16. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  17. Patients have been informed about the nature of study, and have agreed to participate in the study, and signed the informed consent form prior to participation in any study-related activities.
  18. Resolution of all acute toxic effects of prior anti-cancer therapy to grade 1

Exclusion Criteria:

  1. HR or HER2 unknown disease.
  2. HER2-positive disease based on local laboratory results (performed by IHC / ISH test).
  3. Locally ABC candidate for curative treatment.
  4. Formal contraindication to endocrine therapy defined as visceral crisis and rapidly or symptomatic progressive visceral disease.
  5. Prior therapy with any other CDK4/6 inhibitor different from palbociclib.
  6. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated and are clinically stable off anticonvulsants and steroids for at least 4 weeks before randomization.
  7. Patients are currently receiving food or drugs known to be strong inducers or inhibitors of CYP3A4.
  8. Current or prior malignancy which could affect compliance with the protocol or interpretation of results. Patients with curatively- treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinoma in situ, among others, are generally eligible.
  9. No other systemic therapy for metastatic disease including chemotherapy, immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine therapy excluding first-line palbociclib-based regimen.
  10. Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 2 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study.
  11. Radiotherapy or limited-field palliative radiotherapy within 7 days prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade ? 1 and/or from whom ? 25% of the bone marrow has been previously irradiated.
  12. Use of concurrent investigational agents or other concomitant anticancer therapies.
  13. Active bleeding diathesis, previous history of bleeding diathesis, or chronic anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon as it is used as prophylaxis intention).
  14. Serious concomitant systemic disorder (e.g., active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator).
  15. Unable to swallow capsules or tablets.
  16. History of malabsorption syndrome or other condition that would interfere with enteral absorption.
  17. Any of the following within 6 months of randomization:

    myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI-CTCAE v.5.0 grade ?2, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.

  18. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade ? 2.
  19. Known hypersensitivity to palbociclib or any of its excipients.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: María Zafra+34 687 246 755[email protected]
Contact: Alicia García+34 611 261 467[email protected]
Listed Location Countries  ICMJE France,   Germany,   Italy,   Spain,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03809988
Other Study ID Numbers  ICMJE MedOPP068
2017-002781-48 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Study Leaflet V2_20190115 with study design, primary objetive, inclusion criteria and exclusion criteria
Supporting Materials:Study Protocol
Time Frame:During recruitment period
Access Criteria:Oncology department
Responsible Party MedSIR
Study Sponsor  ICMJE MedSIR
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:José PerezMedSIR
PRS Account MedSIR
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP